

Letters

Toujours Gaia

Charles Mann's article "Lynn Margulis: Science's unruly Earth mother" (Research News, 19 Apr., p. 378) was vastly entertaining and spicily written, an example of the new Kitty Kelley school of science journalism. What made it unusual was that the victim of the contumely and scorn was not a public figure, or an entertainer, but a working scientist.

Lynn Margulis is among the most eminent of living biologists, a scientist of stature superior to those selected to denounce her. She is the staunchest of colleagues I have known in 50 years of scientific research, and the sharpest of my critics. I feel a sense of outrage when attacks on her reputation are made because she almost alone among biologists chose to collaborate with me and to share my view of Gaia theory as a straight piece of hard science up for trial. It would have been much easier for her to have remained secure and rested on the laurels worthily gained from the acceptance of her own radical contribution, the endosymbiont hypothesis.

I admit that we have often been provocative. We had to be or our work would have been ignored. I now realize that our provo-

cation was a mistake. Nothing we could say or offer as evidence would convince the closed minds of our opponents. In the case of discoveries such as the global distribution of the chlorofluorocarbons and the finding that dimethyl sulfide is the natural sulfur carrier, I have found that the initial scorn and rejection was soon followed by the development of the topic as a major scientific interest. To the real scientists I say, be patient and don't knock Gaia too hard; before long she may be paying your grants.

JAMES E. LOVELOCK
Coombe Mill,
St. Giles on the Heath,
Launceston PL15 9RY, United Kingdom

Once again neo-Darwinism has received the death sentence, this time from Lynn Margulis. Asserting that the theory is "in a complete funk," Margulis says that speciation and evolutionary novelties are based on the accumulation of symbionts and not mutations.

Before we throw mutations on the scrap heap, however, we should remember the large body of fact showing that both evolution and speciation are based on changes in genes. While there are occasional reports of adaptive change in prokaryotes due to cytoplasmic factors (1), the vast majority of evolutionary changes in both prokaryotes


and eukaryotes occurs at chromosomal genes (2). If Margulis' hypothesis were true, adaptive changes in the phenotype would frequently segregate as cytoplasmic factors or cellular organelles.

The same is true for speciation. While hybrid sterility can occasionally be caused by parasitic bacteria (3), nearly all genetic analyses show that reproductive isolation between species is caused by changes in genes and not by symbionts. This holds for both prezygotic isolation (4) (mating discrimination and self-fertility in plants) and postzygotic isolation (5) (hybrid sterility and inviability). In some cases the genes have been sequenced or mapped to quite restricted sections of the chromosomes (6).

It could be argued that although the small adaptive changes amenable to genetic analysis are based on mutations, large evolutionary novelties are still due to symbionts. This question will remain unanswered until we know the developmental-genetic basis for such novelties. But until Margulis can explain how such complex adaptations as wings, jaws, flowers, and operons can be caused by symbionts, a genetic explanation seems more likely.

Finally, Margulis' theory does not explain the evolution of the symbionts themselves, unless one believes in an infinite evolution-

DETACHaBEAD® — the solution to positive cell isolation



DETACHaBEAD® is a special polyclonal antibody preparation which disturbs and blocks interaction between Dynabeads®-bound antibody and the antigenic determinant on isolated cells.

Use Dynabeads® with DETACHaBEAD® for positive cell isolation and obtain pure (>99%), viable (>98%) and phenotypically unaltered cells. DETACHaBEAD® efficiently detaches cells in 45 minutes at ambient temperature.

DETACHaBEAD® is approved by Dynal® for detachment of Dynabeads® CD4 (new version), CD8 and CD19.

DYNAL®

Making complicated bioseparations simple, rapid and reliable.

DYNAL HEAD OFFICE: DYNAL AS, P.O.BOX 158 SKØYEN, N-0212 OSLO, NORWAY, TEL.: (+472) 52 94 50, FAX: (+472) 50 70 15, TELEX: 79133 DYNAL N

DEUTSCHE DYNAL GmbH, Schaartor 1
Postfach 11 19 65, W-2000 Hamburg 11
TEL.: (040) 36 68 11
FAX: (040) 36 60 40

DYNAL (U.K.) LTD., 26 Grove St.
New Ferry, Wirral, L62 5AZ
TEL.: (051) 644 6555
FAX: (051) 645 2094

DYNAL INC., 475 Northern Blvd.
Great Neck, NY 11021 USA
TEL.: (516) 829 0039
FAX: (516) 829 0045

NIHON DYNAL K.K., 1-1-9 Atago
Minato-Ku, TOKYO 105
TEL.: (03) 3435 1558
FAX: (03) 3435 1526

ary regress of microorganisms swallowing ever smaller microorganisms.

JERRY COYNE

Department of Ecology and Evolution,
University of Chicago,
1101 East 57th Street,
Chicago, IL 60637

REFERENCES

1. N. Cleckner, *Ann. Rev. Genet.* 15, 341 (1981).
2. J. Clausen and W. M. Hiesey, *Carnegie Inst. Wash. Publ.* 615 (1958); T. Dobzhansky, *Genetics of the Evolutionary Process* (Columbia Univ. Press, New York, 1970).
3. N. Somerson, L. Ehrman, J. Kocka, F. J. Gottlieb, *Proc. Natl. Acad. Sci. U.S.A.* 81, 282 (1984); A. A. Hoffmann and M. Turelli, *Genetics* 119, 435 (1988).
4. C. C. Tan, *Genetics* 31, 558 (1946); E. Zouros, *ibid.* 97, 703 (1981); M. R. Nacnair and Q. J. Cumbe, *ibid.* 122, 211 (1989).
5. H. J. Muller and G. Pontecorvo, *Science* 146, 199 (1940); J. A. Coyne and H. A. Orr, in *Speciation and Its Consequences*, D. Otte and J. A. Endler, Eds. (Sinauer, Sunderland, MA, 1989), pp. 180-207.
6. J. T. Patterson and A. B. Griffen, *Univ. Texas Publ.* 4445, 212 (1944); R. A. Pickering, *Heredity* 51, 455 (1983); J. A. Coyne and B. Charlesworth, *ibid.* 57, 243 (1986); J. Wittbrodt *et al.*, *Nature* 341, 415 (1989); J.-L. Guénet *et al.*, *Genet. Res.* 56, 163 (1990).

Learning from the Acid Rain Program

The News & Comment account by Leslie Roberts of the National Acid Precipitation Assessment Program (NAPAP) (15 Mar., p.

1302) identifies the difficulties that this program has encountered in the course of its 10-year odyssey. But these difficulties hardly add up to explaining the chief charge—that NAPAP contributed little to the national debate over acid rain policy. The fundamental reasons for this outcome, I believe, were (i) a legislative charter that simply passed to the Executive Branch responsibility for direction of the program and coordination of agencies having different missions and different objectives, and (ii) lack of initiative and leadership at the White House level. The result was that the science and policy of acid rain were placed in separate compartments and kept there for 10 years.

The NAPAP experience provides a lesson for the global change program. Up to now, government discussions about global change policy have floated silently between the State Department and the President's staff, with little visible exposure or regular contact with the Global Change Research Program. It is not too late to do something about this. It should be feasible to link policy and science within a single recognized component of the Executive Office of the President. This would help scientists become aware of and sensitive to critical policy questions and would help policymakers understand the scientific and factual

bases for the issues they must face. By keeping science and policy in separate compartments the Administration sharpens the suspicion that it is stalling to avoid effective actions (1).

ROBERT G. FLEAGLE

Department of Atmospheric Sciences,
University of Washington,
Seattle, WA 98195

REFERENCES

1. R. G. Fleagle, *Clim. Change*, in press.

With respect to the lessons learned from the acid rain program for research on global change, action is already under way to ensure a proper balance of science, assessment, and policy. A statement from the Second World Climate Conference (1, p. vi) specifically calls for

a special initiative [that] would create a network of regional interdisciplinary research centres, located primarily in developing countries, and focusing on all the natural science, social science, and engineering disciplines required to support fully integrated studies of global change and its impacts and policy responses . . . and [to] study the interaction of regional and global policies.

A proposal is already before the world scientific community, international organizations, and national governments to estab-

RAPD™ Primers. Rapid Mapping.

Operon Technologies announces the availability of Random Amplified Polymorphic DNA (RAPD™) primer kits. Developed by du Pont, RAPD™ is a revolutionary new genetic mapping technology that has considerable advantages over RFLP methods. The RAPD™ technique uses single 10-base oligonucleotide primers to amplify DNA polymorphisms, which are useful as genetic markers (Williams *et al.* *Nucleic Acids Res.*, 18 6531-6535). Operon Technologies now has hundreds of RAPD™ primers available for immediate shipment at economical prices. Call for details.

1-800-688-2248

OPERON

OPERON TECHNOLOGIES, INC.

1000 Atlantic Ave., Suite 108 · Alameda CA 94501
Tel. (415) 865-8644 · Fax. (415) 865-5255 · NIHBP 263-00033233

WORLD'S LEADING SUPPLIER OF SYNTHETIC DNA.

RAPD™ is a trademark of E.I. du Pont de Nemours & Co., Inc.

Circle No. 21 on Readers' Service Card



Internat.

To scientists who are engaged in a way-opening approach for the therapeutic use of peptides in human medicine, the Debiopharm Award of S.Fr. 30'000 x2 will be attributed every two years to two researchers working at University or Research Institutes and involved in the peptide research field, chosen by an international jury of research scientists, presided by Prof. M. Mutter (University of Lausanne).

First attribution during the 22nd European Peptide Symposium - Interlaken - Switzerland - 1992.

Deadline for application: March 31, 1992.

Circle No. 41 on Readers' Service Card

DEBIOPHARM

Contact us at:

DEBIOPHARM*

Rue du Crêt, 2
Case Postale 446
1006 Lausanne
Switzerland
Tel. (41) 21.617.05.86
Fax. (41) 21.617.07.01

*DEBIOPHARM:
private and
independent research
institute for
pharmacological and
clinical development.